Study guide

9.2 Continuous Quality Improvement & Quality Related Events

Massachusetts MPJE Pharmacy Jurisprudence Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Federal Drug Law & Regulatory Foundations

1.1 Federal Acts & Agencies 1.2 Drug Supply Chain Security & Adulteration/Misbranding 1.3 Poison Prevention & Special Packaging Standards

2 Chapter 2: Federal Controlled Substances Act (CSA) Governance

2.1 CSA Scheduling, Registration & Ordering 2.2 Controlled Substance Inventory, Theft & Disposal 2.3 Corresponding Responsibility & DEA Red Flags

3 Chapter 3: Massachusetts Board Authority, Licensure & Continuing Education

3.1 Board of Registration in Pharmacy: Structure & Enforcement 3.2 Pharmacist Licensure, Reciprocity & Renewal 3.3 Continuing Education Requirements

4 Chapter 4: Massachusetts Pharmacy Personnel & Supervision

4.1 Pharmacy Interns: Licensure, Hours & Preceptors 4.2 Pharmacy Technician Licensure Tiers & Scope 4.3 Supervisory Ratios & Direct Supervision 4.4 Manager of Record: Duties, Appointment & Reporting

5 Chapter 5: Prescription Validity, Prescriber Authority & Opioid Limits

5.1 Elements of a Valid Massachusetts Prescription 5.2 Prescriber Authority & the Massachusetts Controlled Substances Registration 5.3 The Massachusetts Electronic Prescribing Mandate 5.4 M.G.L. c. 94C, Massachusetts Schedules & Prescription Validity Windows 5.5 Opioid Prescribing Limits & Partial Fill Rights

6 Chapter 6: Refills, Transfers, Recordkeeping & Emergency Dispensing

6.1 Refill Limits, Sequential Schedule II Prescriptions & Partial Fills 6.2 Prescription Transfers & Pharmacy Recordkeeping 6.3 Out-of-State Prescriptions 6.4 Emergency Dispensing: Oral Schedule II Orders & Schedule VI Emergency Supplies

7 Chapter 7: Product Selection, Labeling & Patient Care Standards

7.1 Mandatory Interchange & the Massachusetts List of Interchangeable Drug Products 7.2 Container Labeling, MedGuides & Patient Package Inserts 7.3 Patient Counseling, Profiles & Drug Utilization Review 7.4 Pharmacist Administration of Drugs & Vaccines 7.5 Returning, Reusing & Disposing of Dispensed Drugs

8 Chapter 8: MassPAT, Nonprescription Products, Public Health & Privacy

8.1 MassPAT: Prescription Monitoring Program Query & Reporting 8.2 Naloxone, Syringes & Standing Orders 8.3 Patient Privacy (HIPAA) & Massachusetts Privacy Rules 8.4 Nonprescription, Behind-the-Counter & Restricted OTC Products

9 Chapter 9: Pharmacy Facilities, Security, Automation & Quality

9.1 Pharmacy Licensure, Facilities & Required References 9.2 Continuous Quality Improvement & Quality Related Events 9.3 Pharmacy Practice Automation & Automated Dispensing Devices 9.4 Security, Delivery, Central Fill & Non-Resident Practice

10 Chapter 10: Compounding, Hazardous Drugs & Expanded Pharmacist Practice

10.1 Non-Sterile Compounding: USP <795> & the Massachusetts Overlay 10.2 Sterile Compounding: USP <797> & the Massachusetts Overlay 10.3 Hazardous Drugs & USP <800> 10.4 Collaborative Drug Therapy Management

11 Chapter 11: The MPJE Blueprint, Delivery & Scoring

11.1 How the MPJE Is Built, Delivered and Scored

9.2 Continuous Quality Improvement & Quality Related Events

Key Takeaways Explain This Topic AI

Continuous quality improvement is governed by 247 CMR 15.00 — not by 247 CMR 9.00 — and every pharmacy must establish a CQI programme to detect, document, assess and prevent quality related events.

A CQI programme must designate a responsible individual, identify and document QREs, minimise their impact on patients, analyse the data for causes and contributing factors, use the findings to change systems and workflow, and provide CQI education to pharmacy personnel at least annually.

All pharmacy personnel must bring a QRE to the pharmacist on duty or the Manager of Record immediately, and the pharmacist must immediately notify the patient, notify the prescriber where professional judgement indicates, give directions for correcting the error and minimise the negative impact.

A QRE must be initially documented by the discovering pharmacist within 24 hours of discovery or notification.

QRE records are retained for a minimum of two years from the date of the QRE report, filed in an orderly manner by date, and may be stored off site.

Last updated: August 2026

Continuous Quality Improvement & Quality Related Events

Important

Cite 247 CMR 15.00. Continuous quality improvement has its own chapter. It is not part of 247 CMR 9.00, and the reporting duties that attach to serious outcomes are in a third chapter again, 247 CMR 20.00. Three chapters, three different jobs.

The Programme — 247 CMR 15.02

Each pharmacy shall establish a Continuous Quality Improvement (CQI) Program for the purpose of detecting, documenting, assessing and preventing Quality Related Events (QREs) . At a minimum, a CQI programme shall include provisions to:

  • designate an individual or individuals responsible for monitoring compliance with 247 CMR 15.00;
  • identify and document QREs ;
  • minimise the impact of QREs on patients ;
  • analyse the data collected in response to QREs to assess causes and any contributing factors;

use the findings of the analysis to formulate an appropriate response and develop pharmacy systems and workflow processes designed to prevent QREs; and

provide ongoing education at least annually in the area of CQI to pharmacy personnel.

The six elements are a checklist, and "at least annually" is the only frequency the regulation specifies.

Discovery and Immediate Response — 247 CMR 15.03(1)

All pharmacy personnel shall be trained to bring any QRE to the attention of the pharmacist on duty or the pharmacist Manager of Record immediately upon discovery.

The pharmacist who has discovered or been informed of a QRE shall immediately provide:

notification to the patient or the patient's representative , to the prescriber (if indicated in the professional judgement of the pharmacist) , and to other members of the health care team;

directions for correcting the error ; and

instructions for minimising the negative impact on the patient .

Warning

Patient notification is unqualified; prescriber notification is not. The regulation requires notification to the patient or the patient's representative. Notification of the prescriber is expressly conditioned on the pharmacist's professional judgement . Reversing these two is a classic distractor.

Documentation — 247 CMR 15.03(2)

A QRE shall be initially documented by the pharmacist who discovered or was informed of it within 24 hours after the QRE is discovered by or described to the pharmacist.

The documentation must be sufficient to permit categorisation and analysis, and must include:

the date the pharmacist discovered or received notification of the QRE, and the name of the person who notified the pharmacy ;

  • the names and titles of the persons recording the QRE information and performing the analysis;
  • a description of the QRE reviewed; and

documentation of the contact with the patient or the patient's representative , with the prescribing practitioner where professional judgement indicated, and with other members of the health care team.

Analysis and Response — 247 CMR 15.03(3)

The investigative and other pertinent data collected in response to QREs shall be analysed individually and collectively to assess the cause and any contributing factors such as system or process failures . The analysis and assessment shall include:

consideration of the effects on quality assurance related to workflow processes, technological support, personnel training and staffing levels ;

any recommended remedial changes to pharmacy policies, procedures, systems or processes; and

the development of indicators that identify means against which the pharmacy's programme intends to measure its standards over a designated period.

Each pharmacy shall then inform pharmacy personnel of the changes to policies, procedures, systems or processes that result from the CQI programme's recommendations.

Important

Staffing levels are named in the regulation. 247 CMR 15.03(3)(a)(1) expressly directs the analysis to consider staffing levels. Read with the Manager of Record's duty to plan and maintain adequate staffing that promotes patient safety, this is the Board telling pharmacies that error analysis cannot stop at "the pharmacist was careless."

Records — 247 CMR 15.04

Each pharmacy shall maintain a written copy of its CQI Program description on the pharmacy premises , readily available to all pharmacy personnel.

Each pharmacy shall maintain a record of all QREs for a minimum of two years from the date of the QRE report .

QRE records shall be maintained in an orderly manner and filed by date .

QRE records may be stored at a site other than the pharmacy where the QRE occurred.

CQI Does Not Discharge the Duty to Report

247 CMR 20.02(3) states plainly that the duty to report improper dispensing resulting in serious injury or death, and the duty to report a serious adverse drug event, are in addition to the CQI requirements of 247 CMR 15.00.

  • Event Where it goes Deadline
  • Any QRE, including a near miss Internal CQI documentation 24 hours to initially document

Improper dispensing causing serious injury or death The Board , under 247 CMR 20.02(1) 7 business days from discovery

Serious adverse drug event from a drug made or compounded at the pharmacy The Board , FDA MedWatch , and the Betsy Lehman Center 7 business days from knowledge by any employee

Records relating to the two reportable events must be kept five years from the date the report is filed (247 CMR 20.02(4)) — not the two years that applies to ordinary QRE records.

Caution

Do not claim a discovery privilege for CQI records. Some states protect pharmacy quality-assurance records from civil discovery by statute. 247 CMR 15.00 contains no such provision, and QRE records must be produced to the Board. Do not counsel colleagues that internal CQI documentation is shielded from disclosure.

Worked Traps

A wrong-strength dispensing is caught by the patient at home and returned unused; the pharmacy does not log it. Violation — the QRE definition reaches events regardless of whether the patient took the medication, and the discovering pharmacist must document within 24 hours.

A pharmacist documents a QRE five days later during a quiet shift. Late — the deadline is 24 hours.

A dispensing error causes hospitalisation and the pharmacy files it only in the CQI log. Violation — 247 CMR 20.02(1) requires a Board report within seven business days.

A root cause analysis concludes "technician error; retrained." Insufficient — 247 CMR 15.03(3) requires consideration of workflow, technological support, training and staffing levels, and the development of measurable indicators.